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In the current study, we investigated whether 17beta-estradiol (E2) induces cyclin E expression and
triggers cyclin E processing via calpain in MCF-7 breast cancer cells. We found that E2 induced
increased expression of cyclin E in a slow and persistent manner, and a rapid yet sustained process-
ing of cyclin E. In addition, estrogenic ethanol was able to stimulate cyclin E truncation. Calpeptin or
ALLN greatly suppressed the E2-triggered cyclin E processing and its expression, suggesting a cal-
pain-mediated action for E2. Finally, the E2-induced effects could also be signiﬁcantly suppressed
by BAPTA or U0126, indicating involvement of calcium/ERK signaling. Taken together, these results
show that estrogenmay contribute to both up-regulation and proteolysis of cyclin E through calpain
in MCF-7 cells.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction cancer, we hypothesized that deregulation of cyclin E might beCyclin E plays a key role in the G1 to S phase transition of the cell
cycle [1]. Deregulation of cyclin E in breast tumors is characterized
by over-expression of total cyclin E and appearance of its truncated
forms [2]. It has been shown that over-expression of cyclin E is asso-
ciated with tumor progression and that high levels of total or pro-
cessed cyclin E strongly predicts poor prognosis of breast cancer
patients [3–5].Moreover, truncated cyclin E is also observed in other
kinds of tumors and is indicative of poor survival [6–8]. Recently, it is
shown that resistance to letrozole in breast cancer is due to over-
expression of proteolyzed cyclin E [9]. The mechanism(s) whereby
cyclin E is deregulated, however, remains unsolved [10–13].
We previously reported that cyclin E can be truncated in breast
cancer cells into its low-molecular-weight (LMW) forms via cal-
pain by calcium stimulation [10]. Another report shows that
over-expressing cyclin E in breast cancer cells may result in cyclin
E processing [11]. Yet, other literature suggests that intracellular
elastase is responsible for cyclin E proteolysis [12,13]. It is likely
that at least two kinds of intracellular proteases may be responsi-
ble for cyclin E processing. However, it is unclear how these prote-
ases are activated to deregulate cyclin E in living cancer cells. As
estrogen plays an important role in hormone-dependent breastchemical Societies. Published by Eattributable to estrogen through calpain that is over-expressed
and highly active in breast cancer cells and tissues [10].
In the present study, we used estrogen receptor(ER)-positive
MCF-7 breast cancer cells to address whether E2 induces deregula-
tion of cyclin E via calpain. We found that E2 caused increased
expressions of cyclin E mRNA and protein and triggered cyclin E
processing in a sustained manner and that both of these E2-in-
duced effects were calpain-dependent.
2. Materials and methods
2.1. Estrogen treatment
Cells were grown under normal conditions until reaching
60%–70%conﬂuence, and then cultured in phenol red (PR)-freemed-
ium without serum for 24 h. Cells were grown in PR-free medium
with2.5%CS-FBS for 12 hbefore experiment. During treatment, cells
were kept inmediumplus1%CS-FBS for observationof proteolysis or
5%CS-FBS to measure the levels of gene and proteins.
2.2. RT-PCR
PCR was performed with gene-speciﬁc primers followed by PCR
ampliﬁcation; beta-actin was used as a reaction standard. Each PCR
product was analyzed by 2% agarose gel electrophoresis. Authenticlsevier B.V. All rights reserved.
Fig. 1. E2-enhanced increased levels of cyclin E are greatly suppressed by calpain inhibitors in MCF-7 cells. (A) Cells were treated with E2 (10 nM) for 0–24 h. Immunoblotting
was used to determine the levels of protein (a); RT-PCR was performed to observe the levels of mRNA (b). (B) At indicated times after E2 (10 nM) treatment, cells were
prepared for MTT assay to measure proliferation. (C) Cells were pretreated with calpeptin (10 lM) or ALLN (10 lM) for 30 min where indicated, followed by treatment with
E2 (10 nM) for 12 h. The ratios of cyclin E/actin were calculated to evaluate the mRNA or protein levels, with DMSO as vehicle control (#P < 0.01 vs. DMSO; ⁄P < 0.01 vs. E2).
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determined by Quantity One Software (Bio-Rad).
2.3. Western blot analysis
Cells were lyzed in RIPA lysis buffer. Cell lysates were separated
on a 12% SDS–PAGE and transferred to a PVDF membrane (Milli-
pore). Protein bands were visualized by using an enhanced chemi-
luminescence kit (Milipore). Digital images of blots were produced
by Syngene Imaging System and quantiﬁed using the GeneSnap
software (Syngene).
2.4. Statistical analysis
The Student’s t-test or one-way ANOVA was used to calculate
the statistical differences. Data are expressed as mean ± S.E.M.
and P < 0.05 was considered signiﬁcant.
3. Results
3.1. E2-upregulated expression of cyclin E was mediated by calpain in
MCF-7 cells
To conﬁrm whether E2 causes up-regulation of cyclin E, we
treated MCF-7 cells with E2 for 0 h–24 h. We observed that the
protein level of wild type cyclin E was greatly increased in re-
sponse to E2 stimulation, which occurred in a delayed yet sus-
tained manner (Fig. 1Aa) and was concurrent with enhanced cellproliferation (Fig. 1B), indicating increased cyclin E expression pro-
motes cell growth. To test whether cyclin E protein expression re-
sults from its increased gene transcription, we employed RT-PCR to
measure its mRNA levels. We noticed that mRNA levels of cyclin E
increased prior to protein elevation after E2 treatment (Fig. 1Ab).
We further accessed whether calpain is involved in E2-triggered
up-regulation of cyclin E using a pharmacologic method. It was
found that both mRNA and protein expressions of cyclin E stimu-
lated by E2 could be effectively inhibited by calpain inhibitors cal-
peptin or ALLN (Fig. 1C). These observations indicate that E2 may
up-regulate cyclin E expression through calpain.
3.2. E2 induced processing of cyclin E in MCF-7 cells
We ﬁrst observed that 10%CS-FBS in the culture led to cyclin E
processing, while lower serum rendered cyclin E intact (Fig. 2A),
indicating a growth factor-induced effect. To test the E2 action,
we treated cells with E2 of varied concentrations and found that
E2 effectively triggered truncation of wild type cyclin E into an
LMW band similar in size to that observed in breast cancer tissues.
E2 at a concentration of 0.1nM was enough to trigger cyclin E
truncation(Fig. 2B), implying a very sensitive response to E2 stim-
ulation. E2-induced cyclin E truncation occurred in a rapid
(15 min) yet sustained manner, peaked at 1 h and lasting for
hours, and E2 at 10 nM achieved a maximum effect (Fig. 2C).
Additionally, truncated cyclin E appeared coincident with process-
ing of focal adhesion kinase (FAK, positive control [11]), but
not of cyclin D1 (negative control). We further tested a possible
Fig. 2. E2 induces cyclin E processing in MCF-7 cells. Arrows indicate the wild type of relevant proteins and asterisks () show their processed forms (the same below). (A)
Cells were cultured in 0–10%CS-FBS for 12 h. (B) Cells were treated with E2 (0–1000 nM) for 1 h. (C) Cells were treated with E2 (10 nM) for 0–6 h (upper panel), with DMSO as
control (lower panel). (D) Cells were treated with EtOH (0.1%) for 0–3 h. (E) Cells were treated with EGF (0–10 ng/ml) for 24 h with ddH2O as control. After treatments, cell
lysates were prepared and immonoblotted with required antibodies (the same below).
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ethanol triggered a similar truncation of cyclin E (Fig. 2D), which
further indicates that estrogenic activity may contribute to cyclin
E processing. Finally, since EGF receptor mediates calpain activa-
tion [14], we used EGF as a positive control for the E2 action on cal-
pain. Indeed, treatment of MCF-7 cells with EGF resulted in
proteolysis of cyclin E (Fig. 2E), but in a delayed manner (peaked
at 24 h), distinct from the E2-induced rapid effect that peaked
at 1 h. These data also suggest that mitogens such as estrogen
and EGF are implicated in the generation of truncated cyclin E.
3.3. E2-stimulated cyclin E processing required calpain activity
We ﬁrst tested whether E2-triggered cyclin E truncation is
mediated through ubiquitous calpains by observing possible auto-
proteolysis (autolysis) of l-calpain [15] that might be accompa-
nied by truncated cyclin E. We found that E2 (or EtOH)-induced
l-calpain autolysis was indeed concurrent with cyclin E process-
ing upon E2 treatment, but not m-calpain (Fig. 3A), indicating
activated l-calpain in the E2-triggered effect. We further used
calpain inhibitors calpeptin and ALLN to access whether calpain
is implicated in cyclin E processing induced by E2. It was found
that either calpeptin or ALLN had a profound inhibition of E2-trig-
gered cyclin E proteolysis together with its accompanied autolysis
of l-calpain (Fig. 3B and C). To conﬁrm E2-induced calpain acti-
vation in MCF-7 cells, we also observed EGF-stimulated FAK pro-
teolysis, and found that EGF-triggered truncation of FAK [11] with
autolysis of l-calpain could also be signiﬁcantly suppressed by
calpeptin (Fig 3D). Furthermore, as intracellular elastase has been
reported to cause processing of cyclin E in breast caner cells
[12,13], we therefore used an elastase inhibitor to test its possible
effect on the E2 action, yet we found that elastase inhibitor did
not affect the E2-induced proteolysis (Fig. 3B). These data indicate
requirement of calpain activity in the E2-induced truncation of
cyclin E.3.4. E2 triggered calpain-mediated action through calcium/ERK
signaling involving membrane ER (mER)
To further validate E2-triggered calpain activation in ER-posi-
tive MCF-7 cells, we also employed ER-negative MDA-MB-231 cells
as a negative control. Indeed, cyclin E in MDA-MB-231 cells re-
mained almost intact upon E2 treatment (Fig. 4A). On the other
hand, since E2-triggered proteolysis of cyclin E occurred rapidly,
we further addressed whether mER is involved in this process.
We found that E2-BSA indeed produced fast truncation of cyclin
E, indicating an mER-mediated action of E2 (Fig. 4B). As calpain
is downstream of calcium/ERK signaling [14], we therefore used
intracellular calcium chelator BAPTA and ERK inhibitor U0126 to
determine whether calcium/ERK signaling is implicated in the cal-
pain-mediated cyclin E processing. As expected, either BAPTA or
U0126 could effectively suppress cyclin E truncation caused by
E2, yet calcium seemed to play a primary role in the initial effect
of E2 (Fig. 4C).
4. Discussion
Here we show that E2 induced increased expressions of cyclin E
protein and mRNA through calpain in MCF-7 cells. We further
demonstrate that E2 also triggered cyclin E processing in a cal-
pain-dependent way. The observation that estrogenic ethanol
caused a rapid truncation of cyclin E provides further evidence
for alcohol as an E2-like factor [16]. This may partially explain
the mechanism whereby estrogen affects progression of breast
cancer [3,4]. Since calpain is highly activated in breast cells and tu-
mors [10], we propose that the response of breast cancer cells to
estrogen could be ampliﬁed through elevated calpain activity,
leading to increased sensitivity to estrogen in calpain-over-
expressing breast cancer cell. Our observation is consistent with
the report that increased expression of cyclin E activates calpain
which further causes elevated cyclin E expression [11]. It is thus
Fig. 3. E2-induced cyclin E processing is effectively suppressed by calpain inhibitors but not elastase inhibitor. (A) Cells were treated with EtOH (0.25%) or E2 (10 nM) for 1 h.
(B) Cells were pretreated with calpain inhibitor calpeptin (50 lM) or elastase inhibitor IV (EI, 40 lM) for 30 min followed by treatment with E2 (10 nM) for 15 min, with
calpeptin (50 lM) or elastase inhibitor IV (40 lM) used alone. Cell lysates were immunoblotted (a) and histogramic presentation of the same blot was shown (b). (C) Cells
were pretreated with calpeptin (50 lM) or ALLN (40 lM) for 30 min, followed by treatment with E2 for 12 h. (D) Cells were treated with EGF (10 ng/ml) for 24 h, where
necessary, pretreated with calpeptin (50 lM) or treated with calpeptin (50 lM) alone.
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and calpain that could be activated by estrogen in breast cancer
cells.
Estrogen exerts its actions via intracellular and membrane ER,
the latter of which mediates estrogen’s rapid effect. Our data show
that E2-induced fast cyclin E processing involved mER, and that
both calcium and ERK are implicated in the E2-induced effect,
which is consistent with previous literature [17,18]. However,
intracellular calcium seemed more required for E2-triggered rapid
processing of cyclin E. Moreover, autolysis of l-calpain [15] coinci-
dent with E2-induced cyclin E processing implied activation of
l-calpain as one of the mechanisms by which E2 enhances thedevelopment of breast cancer [19]. The delayed, persistent in-
creased expression and rapid yet sustained processing of cyclin E
manifest that E2-initiated extranuclear and intranuclear effects
worked together to deregulate cyclin E. Indeed, knockdown of cy-
clin E over-expression inhibits breast cancer cell growth and sup-
presses tumor development [20]. Our data also help explain how
extracellular function of estrogen is associated with invasion and
metastasis in breast cancer [21].
In conclusion, our data for the ﬁrst time show that E2 induced
over-expression and processing of cyclin E through calpain in
MCF-7 cells, which may involve E2’s intracellular and extracellular
actions. Our data also suggest that targeting calpain may be a
Fig. 4. E2-induced cyclin E processing with l-calpain autolysis is inhibited by
BAPTA or U0126 in MCF-7 cells. (A) ER-negative MDA-MB-231 cells were treated
with E2 of varied concentrations (0–50 nM) for 1 h. (B) MCF-7 cells were treated
with E2-BSA (13 nM) for 15 min. (C) MCF-7 cells were pretreated with U0126
(10 lM) or BAPTA (25 lM) for 30 min where indicated, followed by treatment with
E2 (10 nM) for 15 min (a) or 12 h (b).
896 J. Hou et al. / FEBS Letters 586 (2012) 892–896potential strategy to restore or prevent deregulated cyclin E in
breast cancer cells that over-express cyclin E and its truncated
form.
Acknowledgment
This research was supported by the National Natural Science
Foundation of China Grant 30860093 (to Wang X.D.).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2012.02.018.
References
[1] Koff, A., Giordano, A., Desai, D., Yamashita, K., Harper, J.W., Elledge, S.,
Nishimoto, T., Morgan, D.O., Franza, BR. and Roberts, J.M (1992) Formation and
activation of a cyclin E-cdk2 complex during the G1 phase of the human cell
cycle. Science 257, 1689–1694.[2] Keyomarsi, K., Conte Jr., D., Toyofuku, W. and Fox, M.P. (1995) Deregulation of
cyclin E in breast cancer. Oncogene 11, 941–950.
[3] Wingate, H., Puskas, A., Duong, M., Bui, T., Richardson, D., Liu, Y., Tucker, S.L.,
Van Pelt, C., Meijer, L., Hunt, K. and Keyomarsi, K. (2009) Low molecular
weight cyclin E is speciﬁc in breast cancer and is associated with mechanisms
of tumor progression. Cell Cycle 8, 1062–1068.
[4] Akli, S., Van Pelt, C.S., Bui, T., Multani, A.S., Chang, S., Johnson, D., Tucker, S. and
Keyomarsi, K. (2007) Over-expression of the low molecular weight cyclin E in
transgenic mice induces metastatic mammary carcinomas through the
disruption of the ARF-p53 pathway. Cancer Res. 67, 7212–7222.
[5] Keyomarsi, K., Tucker, S.L., Buchholz, T.A., Callister, M., Ding, Y., Hortobagyi,
G.N., Bedrosian, I., Knickerbocker, C., Toyofuku, W., Lowe, M., Herliczek, T.W.
and Bacus, S.S. (2002) Cyclin E and survival in patients with breast cancer. N.
Engl. J. Med. 347, 1566–1575.
[6] Corin, I., Larsson, L., Bergström, J., Gustavsson, B. and Derwinger, K. (2010) A
study of the expression of Cyclin E and its isoforms in tumor and adjacent
mucosa, correlated to patient outcome in early colon cancer. Acta Oncol. 49,
63–69.
[7] Milne, A.N., Carvalho, R., Jansen, M., Kranenbarg, E.K., van de Velde, C.J. and
Morsink, F.M. (2008) Cyclin E low molecular weight isoforms occur commonly
in early-onset gastric cancer and independently predict survival. J. Clin. Pathol.
61 (3), 311–316.
[8] Davidson, B., Skrede, M., Silins, I., Shih, IeM., Trope, C.G. and Flørenes, V.A.
(2007) Low-molecular weight forms of cyclin E differentiate ovarian
carcinoma from cells of mesothelial origin and are associated with poor
survival in ovarian carcinoma. Cancer 110, 1264–1271.
[9] Akli, S., Bui, T., Wingate, H., Biernacka, A., Moulder, S., Tucker, S.L., Hunt, K.K.
and Keyomarsi, K. (2010) Low-molecular-weight cyclin E can bypass letrozole-
induced G1 arrest in human breast cancer cells and tumors. Clin. Cancer Res.
16, 1179–1190.
[10] Wang, X.D., Rosales, J.L., Magliocco, A., Gnanakumar, R. and Lee, K.Y. (2003)
Cyclin E in breast tumors is cleaved into its low molecular weight forms by
calpain. Oncogene 22, 769–774.
[11] Libertini, S.J., Robinson, B.S., Dhillon, N.K., Glick, D., George, M., Dandekar, S.,
Gregg, J.P., Sawai, E. and Mudryj, M. (2005) Cyclin E both regulates and is
regulated by calpain 2, a protease associated with metastatic breast cancer
phenotype. Cancer Res. 65, 10700–10708.
[12] Porter, D.C., Zhang, N., Danes, C., McGahren, M.J., Harwell, R.M., Faruki, S. and
Keyomarsi, K. (2001) Tumor-speciﬁc proteolytic processing of cyclin E
generates hyperactive lower-molecular-weight forms. Mol. Cell. Biol. 21,
6254–6269.
[13] Nguyen, H.H., Aronchik, I., Brar, G.A., Nguyen, D.H., Bjeldanes, L.F. and
Firestone, G.L. (2008) The dietary phytochemical indole-3-carbinol is a
natural elastase enzymatic inhibitor that disrupts cyclin E protein
processing. Proc. Natl. Acad. Sci. USA 105, 19750–19755.
[14] Glading, A., Chang, P., Lauffenburger, D.A. and Wells, A. (2000) Epidermal
growth factor receptor activation of calpain is required for ﬁbroblast motility
and occurs via an ERK/MAP kinase signaling pathway. J. Biol. Chem. 275,
2390–2398.
[15] Baki, A., Tompa, P., Alexa, A., Molnár, O. and Friedrich, P. (1996) Autolysis
parallels activation of mu-calpain. Biochem. J. 318, 897–901.
[16] Fan, S., Meng, Q., Gao, B., Grossman, J., Yadegari, M., Goldberg, I.D. and Rosen,
E.M. (2000) Alcohol stimulates estrogen receptor signaling in human breast
cancer cell lines. Cancer Res. 60, 5635–5639.
[17] Zhang, L., Li, X., Zhao, L., Zhang, L., Zhang, G., Wang, J. and Wei, L. (2009)
Nongenomic effect of estrogen on the MAPK signaling pathway and calcium
inﬂux in endometrial carcinoma cells. J. Cell. Biochem. 106, 553–562.
[18] Improta-Brears, T., Whorton, A.R., Codazzi, F., York, J.D., Meyer, T. and
McDonnell, D.P. (1999) Estrogen-induced activation of mitogen-activated
protein kinase requires mobilization of intracellular calcium. Proc. Natl. Acad.
Sci. USA 96, 4686–4691.
[19] Storr, S.J., Woolston, C.M., Barros, F.F., Green, A.R., Shehata, M., Chan, S.Y., Ellis,
I.O. and Martin, S.G. (2011) Calpain-1 expression is associated with relapse-
free survival in breast cancer patients treated with trastuzumab following
adjuvant chemotherapy. Int. J. Cancer 129, 1773–1780.
[20] Liang, Y., Gao, H., Lin, S.Y., Goss, J.A., Brunicardi, F.C. and Li, K. (2010) siRNA-
based targeting of cyclin E over-expression inhibits breast cancer cell growth
and suppresses tumor development in breast cancer mouse model. PLoS ONE
5, e12860.
[21] Chakravarty, D., Nair, S.S., Santhamma, B., Nair, B.C., Wang, L., Bandyopadhyay,
A., Agyin, J.K., Brann, D., Sun, L.Z., Yeh, I.T., Lee, F.Y., Tekmal, R.R., Kumar, R. and
Vadlamudi, R.K. (2010) Extranuclear functions of ER impact invasive
migration and metastasis by breast cancer cells. Cancer Res. 70 (1), 4092–
4101.
